Community Research and Development Information Service - CORDIS


NeoStrep Result In Brief

Project ID: 601743
Funded under: FP7-HEALTH
Country: Sweden

A novel vaccine against Streptococcus

European research teams have joined forces to develop a novel vaccine against Streptococcus infections in babies. It will not only prevent infection but lower the risk of generating antibiotic resistant strains.
A novel vaccine against Streptococcus
Group B Streptococcus (GBS) is responsible for 50 % of life-threatening infections in new-born babies leading to severe morbidity, mortality or life-long disabilities. Early or late stage infections after birth may lead to pneumonia, sepsis and meningitis. The main form of intervention involves the administration of prophylactic antibiotics to pregnant women who are at risk of transmitting GBS to infants during childbirth. However, the success of antibiotic treatment is hampered by the emergence of drug resistance.

The key objective of the EU-funded NEOSTREP (Development of group B Streptococcal vaccine to alleviate emerging antibiotic resistance through elimination of current prophylactic antibiotic strategies in GBS prevention) project is to develop a novel vaccine to protect against GBS infection. Based on previous work on animal models, the NEOSTREP vaccine provides improved immunogenicity and covers a wide range of clinical isolates.

During the first part of the study, apart from vaccine manufacture the consortium activities have focused on characterising the nature of immune protection following vaccination. For this purpose, they generated mouse models of GBS colonisation and determined the route and dose of vaccine administration. The cellular and antibody immune responses have been characterised focusing on different IgG subclasses that are capable of crossing the placenta.

Vaccine formulation has been optimised and developed, and the optimal adjuvant has been selected. Currently, efforts are concentrated on drafting the clinical protocol and the toxicology plan and submitting the proposal to the health authorities for approval.

The NEOSTREP vaccine is envisaged to eliminate the threat of GBS infection. It will reduce the use of antibiotics and hence the selective pressure on GBS strains promoting development of further antibiotic resistance. Apart from the obvious health benefits, a vaccine will also minimise the healthcare costs associated with the treatment of GBS.

Related information


Life Sciences


Vaccine, infection, babies, antibiotic resistant, Group B Streptococcus
Record Number: 170349 / Last updated on: 2015-12-29
Domain: Biology, Medicine